Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.
Open Access
- 1 December 1995
- Vol. 50 (12), 1321-1323
- https://doi.org/10.1136/thx.50.12.1321
Abstract
A 28 year old man with asthma, bronchopulmonary aspergillosis, pulmonary thromboembolic disease, and pulmonary hypertension developed Aspergillus fumigatus empyema complicating a pneumothorax. His condition progressively deteriorated despite treatment with intravenous and intrapleural amphotericin B, but improved promptly after substituting nebulised liposomal amphotericin B and oral itraconazole. This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease.Keywords
This publication has 7 references indexed in Scilit:
- Liposomes for controlled delivery of drugs to the lung.Thorax, 1992
- Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patientsJournal of Antimicrobial Chemotherapy, 1991
- Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patientsJournal of Antimicrobial Chemotherapy, 1991
- Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trialJournal of Antimicrobial Chemotherapy, 1991
- Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published CasesClinical Infectious Diseases, 1990
- Treatment of Systemic Fungal Infections With Liposomal Amphotericin BArchives of Internal Medicine, 1989
- Subacute massive pulmonary embolism treated with plasminogen and streptokinase.Thorax, 1983